Contact lens solution permanently yanked
May 30th 2006Bausch & Lomb has decided to permanently remove from marketsworldwide its ReNu with MoistureLoc contact lens cleaning solution,based on data suggesting that the product may increasesusceptibility to Fusarium. The company has proposed theformulation as the potential root cause of the increased relativerisk of Fusarium keratitis.
NIH weighs efficacy of multivitamins, minerals
May 30th 2006An independent panel convened by the NIH Office of MedicalApplications of Research and the Office of Dietary Supplements hasassessed the available evidence of multivitamin/minerals (MVMs) andmade recommendations regarding certain supplements. The panel'srecommendations include the following: the combined use of calciumand vitamin D protects the bone health of postmenopausal women;antioxidants and zinc help nonsmoking adults with early-stage,age-related macular degeneration; and women of childbearing ageshould take folate daily.
Drug abuse awareness campaign launched
May 30th 2006The Consumer Healthcare Products Association has joined forces withthe Partnership for a Drug-Free America to launch an advertisingcampaign designed to curb the abuse of prescription and OTCmedicines and to draw public attention to the substance abuse trendamong teenagers. At dual press conferences held recently inWashington, D.C., and New York, TV, print, and radio public serviceads were unveiled.
Medco reaches tentative settlement
May 30th 2006Medco Health Solutions reached a tentative agreement to pay $163million to settle federal fraud charges stemming from twowhistle-blower suits filed by pharmacists against the giant PBM.Still slated for trial in June, the Medco complaint was filed inDecember 2003 by U.S.
CMS holds off on Medicaid price data
May 30th 2006CMS will not publicly release current average manufacturer prices(AMP) slated to be used to calculate Medicaid reimbursement ongenerics, according to administrator Mark McClellan. With inputfrom pharmacy, the agency has concluded that the definition of AMPmust be revised to reflect the prices retail pharmacies actuallypay for generics.
Part D plans must use standard Rx claim codes
May 30th 2006Beginning July 1, all Medicare Part D drug plans must use approvedstandardized reject codes developed by groups representingpharmacy, PBMs, and insurers. The change from best practice tomandate was announced by CMS administrator Mark McClellan, who saidit is fundamentally important to reduce administrative burdens onpharmacists.
More insulin syringes recalled
May 30th 2006Boca Medical Products and the FDA have notified consumers andhealthcare professionals of an extension of an earlier recall ofUltilet insulin syringes and the additional recall of Closercareinsulin syringes because of bacterial contamination withPaenibacillus. This presents a risk of local infection due to softtissue injection with a contaminated syringe as well as a risk ofintroduction of contaminating organisms into a previously sterilevial.
Approval granted for new Focalin XR labeling
May 30th 2006Results of two studies in patients aged six to 12 years have ledNovartis to update the labeling of dexmethylphenidate HCl (FocalinXR) extended-release capsules. Significant improvements in ADHDsymptoms were observed at every hour up to 12 hours afteradministration of 20 mg of the drug compared with placebo.
Name confusion leads to awareness campaign
May 30th 2006AstraZeneca has launched a campaign directed at healthcareproviders after receiving reports of confusion between brand-namedrugs Toprol-XL (metoprolol succinate), Topamax (topiramate,Ortho-McNeil), and Tegretol (carbamazepine, Novartis) and TegretolXR that have led to medication errors. The effort will aim toincrease awareness of the problem and reinforce accurateprescribing and dispensing of Toprol-XL.
Temporary change in MCV4 recommendations
May 30th 2006Sanofi-Pasteur, manufacturer of the meningococcalpolysaccharide-protein conjugate vaccine (MCV4), has announced ashortage of the vaccine that will last at least through the summerof 2006. Due to the limited supply, CDC is now recommending thatproviders immunize only adolescents at high school entry who havenot previously received MCV4 as well as college freshman living indormitories.
CMS proposes new Part D marketing guidelines
May 30th 2006Remember the long list of do's and don'ts CMS came up with latelast year related to how the Medicare Part D plans are to bemarketed? CMS has proposed new guidelines for the 2007 contractyear and has given only one week's time for the public to comment.
New indication granted for Remicade
May 30th 2006Children with active Crohn's disease will now have a new treatmentoption as the FDA has given the regulatory nod to infliximab(Remicade, Centocor) for the treatment of the disease. Themonoclonal antibody works to reduce the inflammation of the bowelassociated with Crohn's by blocking the action of tumor necrosisfactor-alpha and inducing remission of the condition.
Study says: Rx purchases at drugstores drop
May 22nd 2006Fifty-eight percent of adults have visited a drugstore in the past30 days to make a prescription purchase, a decrease from 62% in2004 and 64% in 2000, according to the results of a recent Vertisstudy. Vertis is a Baltimore, Md.-based provider of targetedadvertising, media, and marketing services.
E-prescribing pays, says RxHub study
May 22nd 2006Electronic prescribing that includes patient-specific formularyinformation could cut a payer's drug spend by 8% to 15% anddrug-spend inflation could be reduced by as much as 1% per year,according to an analysis commissioned by RxHub. An e-prescribingnetwork, RxHub processed more than 26 million requests forpatient-specific eligibility, benefit, and formulary informationlast year and is on track to top 60 million patient events thisyear.
New Hampshire bans Rx data sales
May 22nd 2006New Hampshire is set to become the first state to ban drugcompanies from getting physicians' prescription data. The law wouldprevent all types of pharmacies, PBMs, insurers, and data-miningcompanies from selling, transferring, using, or licensing Rxinformation for any commercial purpose.
Suicide risk higher in young adults on Paxil
May 22nd 2006The FDA and GlaxoSmithKline are notifying healthcare professionalsof changes in the Warnings section of the prescribing informationfor both Paxil (paroxetine) and Paxil CR, after a company-performedmeta-analysis found an increased risk of suicidal behavior in youngadults (aged 18-24) taking the drug (2.19% versus 0.92% onplacebo). The clinical trials analyzed included almost 9,000patients treated with paroxetine and about 6,000 on placebo.
Top PBMs reap Part D windfall, group charges
May 22nd 2006Since the launch of Medicare Part D, the top three PBMs have postedrecord earnings, according to the Association of CommunityPharmacists Congressional Network. At a time when Part Dreimbursements to pharmacies are slow and low, ACP*CN noted thatMedco alone generated $650 million in new Medicare sales for thefirst quarter and that Part D allows PBMs to keep any drug companyrebates instead of passing the savings on to seniors.
OIG settles case with Lincare Holdings
May 22nd 2006The Office of Inspector General (OIG) has entered into a SettlementAgreement and Corporate Integrity Agreement (CIA) with LincareHoldings and its subsidiary Lincare Inc. Lincare providesrespiratory care, infusion therapy, and medical equipment topatients in the home. The settlement resolves allegations thatLincare paid illegal kickbacks and violated the PhysicianSelf-Referral Law (also known as the Stark Law).
Keflex now in higher strengths
May 22nd 2006Advancis Pharmaceutical Corp. has been given the go-ahead to marketits antibiotic Keflex (cephalexin) in two newstrengths-333-mg and 750-mg capsules. The company said thiswill give healthcare providers an easier way to prescribe a totaldaily dose of 1,500 mg.
Insurer expands pill-splitting pilot
May 22nd 2006UnitedHealth Pharmaceutical Solutions has expanded its Half-TabletProgram, in which beneficiaries volunteer to split pills to savemoney on co-pays for medications that can be divided. The drugsalso have similar pricing across dosages and are administered oncedaily.
Part D boosts Rx claim rejection rate
May 22nd 2006Medicare Part D contributed to a 24% jump in the number of Rx drugclaim rejections during the first three months since the drugbenefit began, according to an analysis of claims data by WoltersKluwer Health. The Part D launch was marred by problems with claimsinvolving dual eligibles, who accounted for 64% of enrollees.